Global Hospital Acquired Infection Treatment Market: Growing Geriatric Population Propels Nosocomial Treatment Demand in Developed Economies

The staggering increase in the geriatric population across the world is working as a primary driver for the global hospital acquired infection treatment market, especially in developed nations from Europe. The market is also being propelled by the growing prevalence of nosocomial infections within the neonatal population, coupled by a general lack of efficient surveillance systems that can be used to detect HAIs. Emerging economies are known to be ripe grounds for the proliferation of players in the global hospital acquired infection treatment market due to an overall lack of hygienic conditions within healthcare organizations and the high chances of improper sterilization.

Get a Sample of Research Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17267

The global hospital acquired infection treatment market was valued at US$28.99 bn at the end of 2015 and is expected to expand at a CAGR of 2.7% within a forecast period from 2016 to 2024. By the end of 2024, this market is expected to reach an estimated US$36.61 bn.

Antibacterial Treatment for HAIs in Full Swing

The global hospital acquired infection treatment market can be segmented on the basis of treatment has been classified into antibacterial, antiviral, antifungal, and other treatments. In 2015, the antibacterial drugs segment held the leading share in the global hospital acquired infection treatment market. It is also expected to be the leading segment in the global hospital acquired infection treatment market in terms of growth rate within the forecast period from 2016 to 2024.

The global hospital acquired infection treatment market has been also classified on the basis of common infection types, into urinary tract infections, hospital-acquired pneumonia, bloodstream infections, surgical site infections, and other. In 2015, hospital acquired pneumonia segment led the global hospital infection therapeutics market in terms of share size. Urinary tract infections segment is expected to be the leading segment in terms of growth rate during the forecast period of 2016 to 2024.

North America likely to Continue Lead in Global Hospital Acquired Infection Treatment Market

North America led the global hospital acquired infection treatment market in 2015, followed by the Europe. The top drivers of the markets in these regions were the high prevalence of various nosocomial infections, the growing number of multi-drug resistant microbial pathogens, the growing demand for advanced therapeutics against the said pathogens, and the greater ratio of hospitals per thousand people, particularly in North America.

Europe comprises a very large geriatric demographic for this market, as the elderly are known to be extremely prone to serious and even deadly nosocomial infections as a result of their lowered immunity levels. The elderly therefore are in a greater need of advanced antimicrobial therapeutics, consequently contributing towards the growth of hospital acquired infection treatment market here.

Asia-Pacific represents the leading region in the global hospital acquired infection treatment market on the basis of growth rate, from 2016 to 2024. The leading factor attributed for the high pace of growth of this market is an increasing prevalence of nosocomial infections in the region. Additionally, increasing awareness of nosocomial infections and a constantly evolving healthcare infrastructure, coupled with an increasing expenditure on the healthcare industry will add to the growth of this market in the region.

Browse Full Research Report: http://www.transparencymarketresearch.com/hospital-acquired-infection-treatment-market.html

The top players in the global hospital acquired infection treatment market currently, include Abbott Laboratories, Bayer AG, Pfizer Inc., AstraZeneca Plc., GlaxoSmithKline Plc., Cubist Pharmaceuticals, Inc., Cepheid, Merck & Co., Inc., Johnson & Johnson Services, Inc., Astellas Pharma Inc.,Pfizer, Inc., Cipla Inc., Daiichi Sankyo, Inc., Aridis Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, and F. Hoffmann-La Roche Ltd.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.